Healthcare professionals in the EU are being warned about the risk of anaphylactic reactions in MS patients treated with glatiramer acetate. The EMA issued a warning after a review found evidence of such reactions occurring even years after treatment initiation. Common side effects of the drug include vasodilation, arthralgia, anxiety, and hypertonia. The PRAC committee has recommended a direct communication to healthcare professionals about the risk and the need for prompt identification and treatment of anaphylactic reactions. Cases of fatal reactions have been reported, and treatment with glatiramer acetate must be stopped in case of such a reaction.
Source link
EMA Warns of Anaphylactic Reactions to MS Drug
